



# Arginase - 1 - Based Diagnosis as Indicator of the Risk of HBV - Related HCC

Bitá Moudi<sup>1,2,\*</sup>

<sup>1</sup>Infectious Diseases and Tropical Medicine Research Center, Zahedan University of Medical Sciences, Zahedan, Iran

<sup>2</sup>Department of Histology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran

\*Corresponding author: Bitá Moudi, M.Sc., Department of Histology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran. Postal Code: 98167 - 43175, Tel: +98-5433295794, Fax: +98-5433295794, E-mail: bita.moudi@yahoo.com

Received 2017 April 02; Accepted 2017 April 25.

**Keywords:** Hepatocellular Carcinoma, Chronic Hepatitis B, Arginase - 1

## Dear Editor,

Hepatocellular carcinoma (HCC) is a common primary liver malignancy worldwide with a poor prognosis (1) and is the third leading cause of cancer - related deaths (2).

Chronic hepatitis B (HBV) infection, which can cause liver inflammation, has been seen in many individuals with HCC. In addition, fibrosis and cirrhosis are inevitable complications of the infection, which leads to the death of a patient (3, 4).

Early diagnosis of this can prevent the death of a patient and is a crucial factor in the treatment process (5).

It seems that urea cycle enzymes are reliable marker for hepatocytes. For example, arginase - 1 (Arg - 1), which mainly concentrates in periportal hepatocytes (6), is one of the urea cycle enzymes that is expressed in a healthy liver (7).

Chrzanowska et al., assessed Arg - 1 expression by advanced PCR methods and found decreased expression of Arg - 1 in cirrhotic nodules and HCCs (8).

Recently, we found that the expressions of Arg - 1 significantly reduced in patients with HBV - related HCC compared to the patients with only HBV, which can probably manage the diagnosis process of HCC in a way that is time - consuming. The specificity of Arg - 1, among all groups we tested, was 88.4%. Our data emphasized that Arg - 1 can be one of the best markers for HCC on fine - needle aspiration specimens. The results of this study will be released. We also reported Arg - 1 as a very sensitive marker for hepatocytes, which supports Benjamin et al., conclusion as well (9).

Benjamin et al., (9) found the overall sensitivity to be about 96.0% for Arg - 1 in hepatocytes and hepatocellular neoplasms. In addition, all HCCs in their study were reac-

tive for Arg - 1. Moreover, the study of nonhepatocellular tumors revealed that only 2 non - HCC tumors were reactive for Arg - 1.

Furthermore, proper combination of Arg - 1, with some reliable biomarkers such as HepPar - 1 could increase the specificity, accuracy, and precision of natural history of HBV - related HCC diagnosis. We proposed an algorithm to study the natural history of HCC using 2 markers of malignancy (HepPar - 1 and Arg - 1) and found that the respective specificity of Arg - 1 + HepPar - 1 is 100% when we examined HCC cases that were infected previously with HBV.

In another study, Timek et al., (10) performed a triplet algorithm including Arg - 1, hepatocyte paraffin - 1 (HepPar1), and glypican - 3 on liver specimens. They showed that none of the nonhepatic tumor cases were positive for Arg - 1. A total of 19 HCCs samples responded to all three markers, 9 samples responded with only 1 or 2 markers and only 1 case was negative for all 3 markers. Timek suggested the use of 3 markers in differentiating between HCC and metastatic carcinoma.

In conclusion, most of the Arg - 1 studies demonstrated that Arg - 1 has a high sensitivity and specificity in diagnosis of HBV - related HCC and it seems that Arg - 1 can probably be used in detecting HBV infected patients, which are susceptible to HCC. Arg - 1 can develop as an identifier biomarker in pathology of HCC. In addition, the proper combination of Arg - 1 and some well - known and reliable biomarkers is more effective in the study of natural history of the liver malignancy in different stages.

## References

1. Moudi B, Heidari Z, Mahmoudzadeh-Sagheb H, Alavian SM, Lankarani KB, Farrokh P, et al. Concomitant use of heat-shock protein 70, glu-

- tamine synthetase and glypican-3 is useful in diagnosis of HBV-related hepatocellular carcinoma with higher specificity and sensitivity. *Eur J Histochem*. 2018;**62**(1):2859. doi: [10.4081/ejh.2018.2859](https://doi.org/10.4081/ejh.2018.2859). [PubMed: [29569872](https://pubmed.ncbi.nlm.nih.gov/29569872/)]. [PubMed Central: [PMC5806503](https://pubmed.ncbi.nlm.nih.gov/PMC5806503/)].
- Li H, Wang S, Wang G, Zhang Z, Wu X, Zhang T, et al. Yes-associated protein expression is a predictive marker for recurrence of hepatocellular carcinoma after liver transplantation. *Dig Surg*. 2014;**31**(6):468-78. doi: [10.1159/000370252](https://doi.org/10.1159/000370252). [PubMed: [25632982](https://pubmed.ncbi.nlm.nih.gov/25632982/)].
  - El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. *Gastroenterology*. 2007;**132**(7):2557-76. doi: [10.1053/j.gastro.2007.04.061](https://doi.org/10.1053/j.gastro.2007.04.061). [PubMed: [17570226](https://pubmed.ncbi.nlm.nih.gov/17570226/)].
  - Moudi B, Heidari Z, Mahmoudzadeh-Sagheb H. Impact of host gene polymorphisms on susceptibility to chronic hepatitis B virus infection. *Infect Genet Evol*. 2016;**44**:94-105. doi: [10.1016/j.meegid.2016.06.043](https://doi.org/10.1016/j.meegid.2016.06.043). [PubMed: [27346643](https://pubmed.ncbi.nlm.nih.gov/27346643/)].
  - Tawada A, Kanda T, Yokosuka O. Current and future directions for treating hepatitis B virus infection. *World J Hepatol*. 2015;**7**(11):1541-52. doi: [10.4254/wjh.v7.i11.1541](https://doi.org/10.4254/wjh.v7.i11.1541). [PubMed: [26085913](https://pubmed.ncbi.nlm.nih.gov/26085913/)]. [PubMed Central: [PMC4462692](https://pubmed.ncbi.nlm.nih.gov/PMC4462692/)].
  - Sekine S, Ogawa R, McManus MT, Kanai Y, Hebrok M. Dicer is required for proper liver zonation. *J Pathol*. 2009;**219**(3):365-72. doi: [10.1002/path.2606](https://doi.org/10.1002/path.2606). [PubMed: [19718708](https://pubmed.ncbi.nlm.nih.gov/19718708/)].
  - Multhaupt H, Fritz P, Schumacher K. Immunohistochemical localisation of arginase in human liver using monoclonal antibodies against human liver arginase. *Histochemistry*. 1987;**87**(5):465-70. [PubMed: [3323144](https://pubmed.ncbi.nlm.nih.gov/3323144/)].
  - Chrzanowska A, Gajewska B, Baranczyk-Kuzma A. Arginase isoenzymes in human cirrhotic liver. *Acta Biochim Pol*. 2009;**56**(3):465-9. [PubMed: [19636440](https://pubmed.ncbi.nlm.nih.gov/19636440/)].
  - Yan BC, Gong C, Song J, Krausz T, Tretiakova M, Hyjek E, et al. Arginase-1: a new immunohistochemical marker of hepatocytes and hepatocellular neoplasms. *Am J Surg Pathol*. 2010;**34**(8):1147-54. doi: [10.1097/PAS.0b013e3181e5dffa](https://doi.org/10.1097/PAS.0b013e3181e5dffa). [PubMed: [20661013](https://pubmed.ncbi.nlm.nih.gov/20661013/)]. [PubMed Central: [PMC3160135](https://pubmed.ncbi.nlm.nih.gov/PMC3160135/)].
  - Timek DT, Shi J, Liu H, Lin F. Arginase-1, HepPar-1, and Glypican-3 are the most effective panel of markers in distinguishing hepatocellular carcinoma from metastatic tumor on fine-needle aspiration specimens. *Am J Clin Pathol*. 2012;**138**(2):203-10. doi: [10.1309/AJCPKIZC9WNHCCMU](https://doi.org/10.1309/AJCPKIZC9WNHCCMU). [PubMed: [22904131](https://pubmed.ncbi.nlm.nih.gov/22904131/)].